Glycosylation is the most abundant and diverse form of post-translational modification of
proteins that is common to all eukaryotic cells. Enzymatic glycosylation of proteins involves a …

Efforts to develop anti-cancer therapies have largely focused on targeting the epithelial
compartment, despite the presence of non-neoplastic stromal components that substantially …

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor patient
survival. Toward understanding the underlying molecular alterations that drive PDAC …

Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Abstract Carbohydrate antigen 19-9 (CA19-9) is the best validated biomarker and an
indicator of aberrant glycosylation in pancreatic cancer. CA19-9 functions as a biomarker …

The hexosamine biosynthesis pathway (HBP) produces uridine diphosphate-N-acetyl
glucosamine, UDP-GlcNAc, which is a key metabolite that is used for N-or O-linked …

Abstract Carbohydrate antigen 19-9 (CA 19-9) is a cell surface glycoprotein complex most
commonly associated with pancreatic ductal adenocarcinoma (PDAC). Koprowski first …

Cancer is a deadly disease that encompasses numerous cellular modifications. Among
them, alterations in glycosylation are a proven reliable hallmark of cancer, with most …

Given the role of myeloid cells in T cell activation and in the antitumor response, targeting
checkpoint molecules expressed on this population represents a promising strategy to …

A priority in cancer research is to innovate therapies that are not only effective against tumor
progression but also address comorbidities such as cachexia that limit quality and quantity …